Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
391 USD | -1.72% | +0.32% | +27.56% |
05-01 | Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing | MT |
04-24 | Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.6 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.56% | 12.3B | C+ | ||
+26.50% | 42.68B | B- | ||
-4.13% | 42.4B | B | ||
+45.32% | 40.04B | A | ||
-6.20% | 28.31B | C | ||
+6.64% | 24.94B | B- | ||
-21.53% | 18.96B | B | ||
-2.94% | 11.95B | C+ | ||
-1.76% | 11.55B | B+ | ||
+17.71% | 11.32B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEDP Stock
- Ratings Medpace Holdings, Inc.